Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s share price was down 5.5% during mid-day trading on Friday . The stock traded as low as $21.30 and last traded at $21.31. Approximately 813,160 shares were traded during mid-day trading, an increase of 145% from the average daily volume of 331,782 shares. The stock had previously closed at $22.56.

Several equities analysts have issued reports on NTLA shares. Credit Suisse Group boosted their price target on Intellia Therapeutics from $24.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday, November 3rd. ValuEngine raised Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 22nd. Jefferies Group LLC set a $42.00 target price on Intellia Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Leerink Swann upped their target price on Intellia Therapeutics from $29.00 to $37.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 31st. They noted that the move was a valuation call. Finally, Wedbush reaffirmed an “ourperform” rating and set a $25.00 target price (down from $29.00) on shares of Intellia Therapeutics in a research report on Wednesday, September 27th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $30.17.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Tuesday, October 31st. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.06. Intellia Therapeutics had a negative return on equity of 28.01% and a negative net margin of 215.92%. The company had revenue of $7.30 million for the quarter, compared to analyst estimates of $5.83 million. During the same period in the prior year, the firm earned ($0.22) earnings per share. Intellia Therapeutics’s revenue for the quarter was up 49.0% on a year-over-year basis. equities analysts forecast that Intellia Therapeutics, Inc. will post -1.68 EPS for the current fiscal year.

Large investors have recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in shares of Intellia Therapeutics during the second quarter worth approximately $101,000. Nisa Investment Advisors LLC purchased a new stake in Intellia Therapeutics in the 2nd quarter valued at $134,000. Bank of Montreal Can raised its position in Intellia Therapeutics by 1,031.7% in the 2nd quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock valued at $127,000 after buying an additional 7,222 shares during the last quarter. Nationwide Fund Advisors raised its position in Intellia Therapeutics by 117.7% in the 2nd quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock valued at $129,000 after buying an additional 4,351 shares during the last quarter. Finally, State of Wisconsin Investment Board purchased a new stake in Intellia Therapeutics in the 2nd quarter valued at $160,000. 48.89% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Intellia Therapeutics, Inc. (NTLA) Trading Down 5.5%” was first published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.watchlistnews.com/intellia-therapeutics-inc-ntla-trading-down-5-5/1724678.html.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.